To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

HR 679 nullifies specific changes the Food and Drug Administration (FDA) made in January 2023 to the safety rules (REMS) for the abortion pill mifepristone. The bill prohibits the FDA from implementing any future safety rules for mifepristone that are substantially similar to the nullified changes. This directly affects the FDA's regulatory authority over mifepristone, which could impact how healthcare providers prescribe the medication and how patients access it. The bill focuses solely on reversing the FDA's 2023 modifications without altering the drug's broader approval status.